MedTrace Logo

CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation

NCT01336478 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-06-08

No results posted yet for this study

Summary

The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic stem cell transplantation.

Conditions

  • Haematological Malignancies
  • Allogeneic Stem Cell Transplant
  • CD56+CD3- NK Cells

Interventions

PROCEDURE

Infusion of donor derived ex-vivo selected NK cells to patients after transplant

Infusion of donor derived ex-vivo selected NK cells to patients after transplant

PROCEDURE

Haematology / Blood chemistry sampling

Haematology / Blood chemistry sampling, collection of blood for ancillary lab research

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Katy Rezvani, MD · Imperial College Healthcare NHS Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336478 on ClinicalTrials.gov